Literature DB >> 14565806

Allopurinol as a cardioprotectant during coronary artery bypass graft surgery.

Nicole A Weimert1, William F Tanke, J Jason Sims.   

Abstract

OBJECTIVE: To examine the role of allopurinol as a cardioprotectant during coronary artery bypass graft (CABG) surgery. DATA SOURCES: A search of MEDLINE (1966-October 2002) was performed using the following terms: allopurinol, xanthine oxidase, oxygen free radical, and coronary artery bypass. References evaluated were limited to English-language and human studies, yielding 41 citations, 13 of which were found suitable. The 5 largest studies are discussed. DATA SYNTHESIS: Multiple studies with various doses have evaluated the effects of allopurinol on outcomes in CABG patients. These studies found that allopurinol can reduce in hospital mortality, improve cardiac performance, reduce incidence of arrhythmias, reduce markers of ischemia and free-radical generation, and reduce the need for inotropic support. However, these findings were not consistent between all studies.
CONCLUSIONS: Allopurinol may reduce the incidence of CABG complications. Although the optimal dose has not been determined, reviewed literature suggests that patients should receive at least 600 mg one day prior to surgery, as well as at least 600 mg on the day of surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14565806     DOI: 10.1345/aph.1D023

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  2 in total

1.  Xanthine oxidase and uric Acid in atrial fibrillation.

Authors:  Panagiotis Korantzopoulos; Konstantinos P Letsas; Tong Liu
Journal:  Front Physiol       Date:  2012-05-24       Impact factor: 4.566

2.  Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation.

Authors:  Lin-Lin Kang; Dong-Mei Zhang; Chun-Hua Ma; Jian-Hua Zhang; Ke-Ke Jia; Jia-Hui Liu; Rong Wang; Ling-Dong Kong
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.